SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
PRTA reported Q3 2026 results. The price and volatility reaction is pending.
PRTAearnings

Earnings reactions, page 6

Prothena Corporation plc (PRTA) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Net loss was $16.5 million for the third quarter of 2026 and $2.4 million for the first nine months of 2026.
  • Total revenue was $0.6 million for the third quarter of 2026 and $52.7 million for the first nine months of 2026.
  • Basic and diluted net loss per ordinary share was $0.32 for the third quarter of 2026 and $0.05 for the first nine months of 2026.
  • Research and development expenses totaled $8.4 million for the third quarter of 2026 and $29.9 million for the first nine months of 2026.
  • General and administrative expenses totaled $10.6 million for the third quarter of 2026 and $34.2 million for the first nine months of 2026.
  • Cash, cash equivalents and restricted cash position was $272.2 million as of September 30, 2026.

Guidance

  • Full year 2026 net cash used in operating and investing activities is expected to be $18 to $23 million.
  • The company expects to end 2026 with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash.
  • Estimated full year 2026 net loss is expected to be $25 to $30 million.
  • Estimated full year 2026 net loss includes an estimated $26 million of non-cash share-based compensation expense.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →